Novo Nordisk regains Novorapid supply capacity

After a challenging period, Novo Nordisk can once again supply fast-acting insulin product Novorapid, Dagens Pharma reports.

Photo: Jacob Ehrbahn/Politiken

Supply chain issues concerning Novo Nordisk’s fast-acting insulin product Novorapid (insulin aspart) have been resolved, industry media Dagens Pharma reports.

Logistical challenges involved in transporting the drug from the US had meant that Novo Nordisk has struggled to supply vials of the injectable treatment since early May, a problem that also affected parallel importers Paranova, 2care4, and Orifarm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs